Story perspectives

Breakthroughs in CLL Treatment Offer New Hope

2/21/2025

31 6

Summary

Story summary

Chronic lymphocytic leukemia (CLL) may still be incurable, but hope shines brighter with recent advancements in treatment. The phase III AMPLIFY trial revealed that combining acalabrutinib with venetoclax significantly enhances progression-free survival, while the CRISTALLO trial showcased remarkable success in achieving undetectable minimal residual disease with venetoclax and obinutuzumab. These breakthroughs mark a pivotal shift towards targeted therapies in CLL care.

1 of 1

Story summary

Chronic lymphocytic leukemia (CLL) may still be incurable, but hope shines brighter with recent advancements in treatment. The phase III AMPLIFY trial revealed that combining acalabrutinib with venetoclax significantly enhances progression-free survival, while the CRISTALLO trial showcased remarkable success in achieving undetectable minimal residual disease with venetoclax and obinutuzumab. These breakthroughs mark a pivotal shift towards targeted therapies in CLL care.